Medical Big Data: Both an Opportunity and a Challenge for Chinese Pharmaceutical Innovation

Abstract

Medical big data, adopted as a public health database, whereby pharmaceutical professionals have been having easier access to multiple viewpoints and enormous amounts of medical data in a dynamic and intuitive presentation during pharmaceutical R&D (research and development), has brought more opportunities for pharmaceutical innovation. However, there are currently few platforms in China for exchanging and linking medical big data. By using an examination of the current scenario based on opportunities and challenges, we suggest the essential foundations and prospective advantages of medical big data in this paper. We also present viable solutions through developing an assessment system, protecting intellectual property rights, and encouraging professional development in the fields of technology and medicine to halt or even reverse China's fragmented and inadequate medical wisdom system.